PD-L1 Negative
4 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer (NCT05382299) | Gilead Sciences | 2022-07-20 |
| Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC (NCT04468061) | Dana-Farber Cancer Institute | 2020-07-20 |
| Pembrolizumab Plus Autologous Dendritic Cell Vaccine in Patients with PD-L1 Negative Advanced Mesothelioma Who Have Failed Prior Therapies (NCT03546426) | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | 2019-12-12 |
Track PD-L1 Negative automatically
Every clearance here is in the API, with alerts when new ones post.